TIF News-todelete

A Useful Health & Nutrition Short Guide for the COVID-19 Pandemic by TIF

A Useful Health & Nutrition Short Guide for the COVID-19 Pandemic by TIF

The coronavirus presents many uncertainties, and none of us can completely eliminate the risk of getting infected with COVID-19. Nevertheless, one thing we can do is eat as healthy as…
TIF’s latest Newletter is out now!

TIF’s latest Newletter is out now!

Catch up with our most recent newsletter and get informed about TIF’S activities and achievements in the past few months! If you would also like to receive our news directly…
TIF organises the‘’1st International Informational Forum on New & Innovative Therapies for Haemoglobinopathies’’_12 December 2019

TIF organises the‘’1st International Informational Forum on New & Innovative Therapies for Haemoglobinopathies’’_12 December 2019

  In light of the rapid scientific developments in the field of thalassaemia and Sickle Cell Disease (SCD) – new drugs and gene therapies – which promise to change the…
TIF by the side of thalassaemia patients in Syria

TIF by the side of thalassaemia patients in Syria

  The World Health Organisation (WHO) has contacted the Thalassaemia International Federation (TIF) to request the provision of its expertise and technical support on the thalassaemia care and management of…
FDA Grants Priority Review to Potential Sickle Cell Disease Treatment Voxelotor

FDA Grants Priority Review to Potential Sickle Cell Disease Treatment Voxelotor

  The Food and Drug Administration (FDA) will review an approval application for a drug designed to target the root cause of damage from sickle cell disease (SCD). South San…
TIF releases new video on thalassaemia prevention

TIF releases new video on thalassaemia prevention

  Thalassaemia is a hereditary blood disease that CAN be prevented! But in what ways? ΤΙF’s latest educational video shines a spotlight on the essential aspect of the disease’s prevention,…
Gene Therapy and Thalassaemia: The Patients’ Perspective survey!

Gene Therapy and Thalassaemia: The Patients’ Perspective survey!

  A significant number of gene therapy approaches are currently undergoing clinical trials, some of which are already producing encouraging results. The Bluebird Bio’s gene therapy product, under the name ZYNTEGLO™,…
International Thalassaemia Day: More than 1 in 10 Cypriots carriers of β-thalassaemia

International Thalassaemia Day: More than 1 in 10 Cypriots carriers of β-thalassaemia

  A comprehensive article by Carsten W. Lederer (PhD), Petros Patsali (PhD), Panayiota Papasavva (MD, MSc), Thessalia Papasavva (PhD) and Marina Kleanthous (PhD, Head of the MGTD), on the thalassaemia…
Gene Therapy for β-Thalassaemia Approaches European Market Approval

Gene Therapy for β-Thalassaemia Approaches European Market Approval

Gene therapy continues to evolve with new emerging treatments finally reaching its promised potential: providing a one-time lifelong cure for even the rarest and most severe of genetic disorders. TIF’s…
زر الذهاب إلى الأعلى